Live Quote · NASDAQSNDXHealthcare · Biotechnology

Syndax Pharmaceuticals, Inc.

$23.61▼ 4.95%($-1.23)

TickerSpark Score

66/100

▌ Solid

33

Valuation

40

Profitability

90

Growth

68

Health

100

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNDX research report →

52-Week Range88% of range

Low

$9.03

Current

$23.61

High

$25.59

Company Overviewwww.syndax.com

About the company

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML).

CEO: Michael A. Metzger
IPO: 2016
Employees: 270
HQ: New York City, NY, US

Price Chart

+140.43% · this period

Valuation

Market Cap: $2.09B
P/E: -8.43
P/S: 9.63
P/B: 49.14
EV/EBITDA: -14.19
Div Yield: 0.00%

Profitability

Gross Margin: 97.96%
Op Margin: -102.93%
Net Margin: -112.01%
ROE: -256.66%
ROIC: -57.76%

Growth & Income

Revenue: $172.35M · 627.84%
Net Income: $-285,422,000 · 10.46%
EPS: $-3.29 · 11.80%
Op Income: $-273,084,000
FCF YoY: -17.56%

Performance & Tape

52W High: $25.59
52W Low: $9.03
50D MA: $20.03
200D MA: $19.88
Beta: 0.37
Avg Volume: 1.92M

Get TickerSpark's AI analysis on SNDX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jul 8, 26	Metzger Michael A	director, officer: Chief Executive Officer	other	32,375	$206.55K
Jul 8, 26	Metzger Michael A	director, officer: Chief Executive Officer	sell	32,375	$784.78K
Jul 8, 26	Metzger Michael A	director, officer: Chief Executive Officer	other	32,375	$206.55K
Jun 11, 26	Botwood Nicholas A.J.	officer: Head of R&D, CMO	other	22,515	$311.16K
Jun 12, 26	Botwood Nicholas A.J.	officer: Head of R&D, CMO	other	31,235	$431.67K
Jun 11, 26	Botwood Nicholas A.J.	officer: Head of R&D, CMO	sell	34,280	$617.04K
Jun 12, 26	Botwood Nicholas A.J.	officer: Head of R&D, CMO	sell	31,235	$566.60K
Jun 12, 26	Botwood Nicholas A.J.	officer: Head of R&D, CMO	other	31,235	$431.67K
Jun 1, 26	Goldan Keith A.	officer: Chief Financial Officer	sell	1,177	$22.35K
Jun 1, 26	Metzger Michael A	director, officer: Chief Executive Officer	sell	6,847	$130.02K

Coverage · SNDX

Our SNDX coverage

Recent articles, reports, and earnings notes.

View all →

IPO

Should You Buy the Parabilis Medicines IPO? Here's the Setup

Parabilis Medicines (NASDAQ: PBLS) is expected to list on 2026-06-10, with shares priced at $17.00 to $19.00. The company is offering 25,000,000 shares and is targeting a $546,250,000 market cap. The bull case is a differentiated oncology platform; the bear case is a clinical-stage biotech with no disclosed commercial revenue.